PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

• US 20120065224A1
• Filed: 11/15/2011
• Published: 03/15/2012
• Est. Priority Date: 09/03/2004
• Status: Active Grant

• Current Assignee: Yuhan Corporation
• Original Assignee: Yuhan Corporation
• Inventors: KIM, Jae-Gyu, AHN, Byung-Nak, LEE, Hyouk-Woo, YOON, Suk-Won, YOON, Young-Ae, KIM, Dong-Hoon, KEUM, Se-Hoon, SHIN, Young-Ah, KANG, Heui-Il, CHOI, Ryong, JANG, Sun-Young
• Granted Patent: US 8,513,277 B2
• Time in Patent Office: Days
• US Class Current: 514/300
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.

Claims

1. A compound of the formula (I) or a pharmaceutically acceptable salt thereof:

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R₁ is hydrogen;

a straight or branched C₁-C₆ alkyl group;

a C₁-C₃ alkyl group substituted with one or more substituents selected from the group consisting of methoxy, ethoxy, hydroxy, cyclopropyl, cyclobutyl, cyclohexyl, methylthiazolyl, and 1,3-dioxolanyl;

a straight or branched C₂-C₆ alkenyl group;

a straight or branched C₂-C₆ alkynyl group;

cyclopropyl;

cyclopentyl;

or a benzyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, methyl, and methoxy,

R₂ is a straight or branched C₁-C₃ alkyl group,

R₃ is hydrogen;

a straight or branched C₁-C₃ alkyl group;

a straight or branched C₂-C₅ alkenyl group;

or a benzyl group optionally one or more substituted with halogen, and

R₄ is a benzyloxy group optionally one or more substituted with halogen;

or an amino group substituted with one or two substituents selected from the group consisting of hydrogen, straight or branched C₁-C₅ alkylcarbonyl, phenoxycarbonyl, benzyl optionally one or more substituted with halogen, and benzoyl optionally one or more substituted with halogen.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1, which is selected from the group consisting of:

2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine;

2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

1,2,3-trimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-ethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-propyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

1-allyl-2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-isopropyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

1-isobutyl-2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

1-cyclopropylmethyl-2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-(2-methoxyethyl)-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-([1,3]dioxolan-2-ylmethyl)-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

1-benzyl-2,3-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-(2-fluorobenzyl)-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-(3-fluorobenzyl)-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

2,3-dimethyl-1-(4-fluorobenzyl)-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-benzyl-N-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N,N-di-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-acetyl-N-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-isobutyryl-N-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-benzoyl-N-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-(2-chlorobenzoyl)-N-(4-fluorobenzyl)]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

7-[N-(4-fluorobenzyl)-N-phenoxycarbonyl]amino-1,2,3-trimethyl-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-2-methyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-1,2-dimethyl-4-(4-fluorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-2-methyl-4-(4-chlorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-1,2-dimethyl-4-(4-chlorobenzylamino)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-2-methyl-4-(4-fluorobenzyloxy)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-1,2-dimethyl-4-(4-fluorobenzyloxy)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-2-methyl-4-(4-chlorobenzyloxy)-1H-pyrrolo[3,2-c]pyridine hydrochloride;

3-benzyl-1,2-dimethyl-4-(4-chlorobenzyloxy)-1H-pyrrolo[3,2-c]pyridine hydrochloride, and

a pharmaceutically acceptable salt thereof.

4. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, which comprises:

(a) adding a sodium nitrite solution to a compound of formula (II), followed by reducing the resulting product with tin chloride, to obtain a compound of formula (III);

(b) reacting the compound of formula (III) with a compound of formula (IV) to obtain a compound of formula (V);

(c) performing a cyclization reaction of a compound of formula (V) to obtain a compound of formula (VI);

(d) halogenizing the compound of formula (VI) to obtain a compound of formula (VII);

(e) reacting the compound of formula (VII) with R₄—

H to obtain a compound of formula (Ia); and

(f) reacting the compound of formula (Ia) with R₁—

X to obtain a compound of formula (I);

5. A pharmaceutical composition comprising a therapeutically effective amount of any of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.